Introduction
APOBEC3G, a member of the apolipoprotein B mRNA-editing enzyme catalytic polypeptide (APOBEC) family of proteins homologous cytidine deaminase domains (Jarmuz et al., 2002) , has been identified as a host factor involved in cellular defense mechanism against retroviruses (Harris et al., 2003; Mangeat et al., 2003; Sheehy et al., 2002) . APOBEC3G can either edit the newly synthesized viral DNA or inhibit another site(s) of the viral life cycle (Mangeat et al., 2003; Mariani et al., 2003; Turelli and Trono, 2005; Zhang et al., 2003) . Recently, inhibition of human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus, equine infectious anemia virus, murine leukemia virus and hepatitis B virus by APOBEC3G has been reported (Mangeat et al., 2003; Navarro and Landau, 2004; Noguchi et al., 2005; Rosler et al., 2005) .
Although APOBEC3G resides in HIV-1 permissive cells, such as CD4 + T cells and monocyte-derived macrophages (Chiu et al., 2005) , expression of APOBEC3G has also been identified in other human organs, such as lungs, testes, ovaries, liver and kidney (Chen et al., 2006; Jin et al., 2005; Komohara et al., 2007 Komohara et al., , 2006 Turelli and Trono, 2005) . In addition, APOBEC3G could be induced by interferons (IFNs) in human lymphocytes, macrophage, liver and kidney cells (Bonvin et al., 2006; Chen et al., 2006; Komohara et al., 2007 Komohara et al., , 2006 Peng et al., 2006; Tanaka et al., 2006) . Both type I and type II IFNs play a critical role in the host innate immunity against viral infections. IFN-α is a potent inhibitor of HIV-1 infection of CCR5 + CD4 + human macrophages (BacaRegen et al., 1994; Meylan et al., 1993) . IFN-α is also a potent inducer of APOBEC3G, which overrides HIV-1 vif-mediated neutralization of APOBEC3G protein that pose a threat to efficient HIV-1 replication in macrophages (Peng et al., 2006) . Although it has been demonstrated that APOBEC3G could be induced by type I IFNs in human lymphocytes,
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Abbreviation: APOBEC3G, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; BDNF, brain-derived neurotrophic factor; BMVECs, brain microvascular endothelial cells; CCL3, CC chemokine ligand 3; CCL4, CC chemokine ligand 4; CCL5, CC chemokine ligand 5; CNS, central neurons system; DMEM, Dulbecco's modified Eagle's medium; DSU, densitometry scanning unit; FBS, fetal calf serum; hEGF, human epidermal growth factor; hFGFb, human fibroblast growth factor-basic; HIV-1, human immunodeficiency virus type 1; IFN-α, interferon alpha; IFN-β, interferon beta; IFN-γ, interferon gamma; IL-1β, interleukin-1 beta; IL-4, interleukin-4; IL-6, interleukin-6; IMDM, Iscover's modified Dulbecco's medium; LPS, lipopolysaccharide; NMDA, Nmethyl-D-aspartate; NPC, neural precursor cell; PBL, peripheral blood lymphocytes; RA, retinoic acid; TGF-β1, transforming growth factor beta1; TNF-α, tumor necrosis factor alpha. ☆ This work was supported by the National Institutes of Health grants (DA012815 and DA022177 to W.Z.H.).
